24 Result(s)

Article

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the high efficacy and other benefits of GLP-1RAs, their uptake was...

Vanita R. Aroda, Lawrence Blonde… in Reviews in Endocrine and Metabolic Disorde… (2022)

Article

Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results

iGlarLixi, the once-daily fixed-ratio combination of insulin glargine 100 U/ml and lixisenatide, robustly improves glycaemic control in adults with type 2 diabetes irrespective of previous treatment [oral anti...

Cristian Guja, Francesco Giorgino, Lawrence Blonde, Amar Ali… in Diabetes Therapy (2022)

Article

Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes

Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) ...

Neil Skolnik, Stefano Del Prato, Lawrence Blonde, Gagik Galstyan… in Advances in Therapy (2021)

Article

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study

Injectable therapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin (BI) are well-established agents for people with type 2 diabetes (T2D). This study aimed to investigate real...

Xuejun Victor Peng, Rory J. McCrimmon, Leah Shepherd, Anders Boss… in Diabetes Therapy (2020)

Article

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L

With longer duration and progression of type 2 diabetes (T2D), β-cell function deteriorates and insulin therapy often becomes necessary. Glucagon-like peptide-1 receptor agonists such as lixisenatide that do n...

Lawrence Blonde, Lori Berard, Aramesh Saremi, Yao Huang… in Diabetes Therapy (2020)

Article

Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial

iGlarLixi is a titratable, fixed-ratio combination of insulin glargine (iGlar, 100 units/ml) and the glucagon-like peptide-1 receptor agonist lixisenatide for the treatment of patients with type 2 diabetes. Th...

Lawrence Blonde, Timothy S. Bailey, Jason Chao, Terry A. Dex… in Advances in Therapy (2019)

Article

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician

Real-world studies have become increasingly important in providing evidence of treatment effectiveness in clinical practice. While randomized clinical trials (RCTs) are the “gold standard” for evaluating the s...

Lawrence Blonde, Kamlesh Khunti, Stewart B. Harris, Casey Meizinger… in Advances in Therapy (2018)

Article

Correction to: Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations

The article “Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations”.

Lawrence Blonde, Susana Dipp, Daniel Cadena in Advances in Therapy (2018)

Article

Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations

Type 2 diabetes mellitus (T2DM) is a complex disease, and while lifestyle interventions remain the cornerstone of therapy, most patients will also require pharmacotherapy. Current diabetes treatment guidelines...

Lawrence Blonde, Susana Dipp, Daniel Cadena in Advances in Therapy (2018)

Article

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin

Treatment guidelines recommend a stepwise approach to glycemia management in patients with type 2 diabetes (T2D), but this may result in uncontrolled glycated hemoglobin A1c (HbA1c) between steps. This retrosp...

Lawrence Blonde, Denis Raccah, Elisheva Lew, Juliana Meyers… in Diabetes Therapy (2018)

Article

Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA

Basal insulin (BI) plays an important role in treating type 2 diabetes (T2D), especially when oral antidiabetic (OAD) medications are insufficient for glycemic control. We conducted a retrospective, observatio...

Lawrence Blonde, Luigi Meneghini, Xuejun Victor Peng, Anders Boss… in Diabetes Therapy (2018)

Article

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate

While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart rate (HR), it is insufficiently recognized that the extent varies greatly between the various agonists and is affected by...

Martin Lorenz, Francesca Lawson, David Owens, Denis Raccah… in Cardiovascular Diabetology (2017)

Article

A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures

The randomized, double-blind CANTATA-SU (CANagliflozin Treatment And Trial Analysis Sulfonyl Urea) clinical trial compared the use of canagliflozin (100 mg or 300 mg) and maximally tolerated glimepiride (6–8 m...

Charmi A. Patel, Robert A. Bailey, Ujjwala Vijapurkar… in BMC Health Services Research (2016)

Article

Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone

The time-course when changes in glycemic control and body weight were first manifest in patients with type 2 diabetes mellitus (T2DM) treated with a combination of insulin degludec and liraglutide (IDegLira) w...

Tina Vilsbøll, Jiten Vora, Henrik Jarlov, Kajsa Kvist… in Clinical Drug Investigation (2016)

Article

Effects of canagliflozin on body weight and relationship to HbA_1c and blood pressure changes in patients with type 2 diabetes

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces HbA_1c, body weight and systolic BP (SBP) in patients with type 2 diabetes. As weight loss is known to reduce both HbA_1c and SBP, these analyses ...

William T. Cefalu, Kaj Stenlöf, Lawrence A. Leiter, John P. H. Wilding… in Diabetologia (2015)

Article

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes

Overweight or obesity contributes to the development of type 2 diabetes mellitus (T2DM) and increases cardiovascular risk. Exenatide, a glucagon-like peptide-1 receptor agonist, significantly reduces glycated ...

Lawrence Blonde, Richard Pencek, Leigh MacConell in Cardiovascular Diabetology (2015)

Article

Erratum to: Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus

Lawrence Blonde, Zinnia T. San Juan in Advances in Therapy (2013)

Article

Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus

Combining antihyperglycemic agents with complementary mechanisms of action is a cornerstone of type 2 diabetes mellitus (T2DM) management. Although several fixed-dose combinations (FDCs) are available, represe...

Lawrence Blonde, Zinnia T. San Juan in Advances in Therapy (2012)